45.37
-0.11 (-0.24%)
| Previous Close | 45.48 |
| Open | 45.63 |
| Volume | 620,738 |
| Avg. Volume (3M) | 1,158,790 |
| Market Cap | 9,838,075,904 |
| Price / Earnings (TTM) | 24.52 |
| Price / Earnings (Forward) | 17.89 |
| Price / Sales | 5.02 |
| Price / Book | 2.75 |
| 52 Weeks Range | |
| Earnings Date | 4 Feb 2026 |
| TTM Dividend Yield | 0.52% |
| Profit Margin | 4.68% |
| Operating Margin (TTM) | 25.89% |
| Diluted EPS (TTM) | 0.430 |
| Quarterly Revenue Growth (YOY) | 5.40% |
| Quarterly Earnings Growth (YOY) | 12.50% |
| Total Debt/Equity (MRQ) | 41.36% |
| Current Ratio (MRQ) | 3.37 |
| Operating Cash Flow (TTM) | 680.21 M |
| Levered Free Cash Flow (TTM) | 622.84 M |
| Return on Assets (TTM) | 5.75% |
| Return on Equity (TTM) | 2.67% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bullish | Bullish |
| Diagnostics & Research (Global) | Bullish | Bullish | |
| Stock | Qiagen N.V. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.25 |
|
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%). |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Core |
| % Held by Insiders | 1.61% |
| % Held by Institutions | 86.26% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 60.00 (JP Morgan, 32.25%) | Buy |
| Median | 55.00 (21.23%) | |
| Low | 50.00 (Stifel, 10.21%) | Hold |
| Average | 54.80 (20.79%) | |
| Total | 2 Buy, 3 Hold | |
| Avg. Price @ Call | 50.51 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 06 Feb 2026 | 55.00 (21.23%) | Hold | 50.95 |
| 11 Dec 2025 | 50.00 (10.20%) | Hold | 45.44 | |
| JP Morgan | 06 Feb 2026 | 60.00 (32.25%) | Buy | 50.95 |
| Stifel | 06 Feb 2026 | 50.00 (10.20%) | Hold | 50.95 |
| Deutsche Bank | 22 Jan 2026 | 54.00 (19.02%) | Hold | 54.25 |
| Barclays | 15 Dec 2025 | 55.00 (21.23%) | Buy | 45.44 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 04 Feb 2026 | Announcement | QIAGEN Exceeds Q4 2025 Outlook Driven by Growth Pillars |
| 03 Feb 2026 | Announcement | QIAGEN Showcases QIAsprint Connect High-Throughput Automation System for Labs Worldwide at SLAS 2026 |
| 26 Jan 2026 | Announcement | QIAGEN Appoints Mark Stevenson to Supervisory Board |
| 19 Jan 2026 | Announcement | QIAGEN N.V. to Release Results for Q4 2025 and Hold Webcast |
| 12 Jan 2026 | Announcement | QIAGEN Sets 2026 Priorities to Drive Growth Across Five Pillars Toward Achieving 2028 Goals for Solid Profitable Growth |
| 18 Dec 2025 | Announcement | QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |